article = {COR-2020-12-104}
title = {Impact of Immune Checkpoint Inhibitor on the Survival in Elderly Patients with Non-Small Cell Lung Cancer}
journal = {Clinical Oncology and Research}
year = {2020}
issn = {2613-4942}
doi = {http://dx.doi.org/10.31487/j.COR.2020.12.04}
url = {https://www.sciencerepository.org/impact-of-immune-checkpoint-inhibitor-on-the-survival-in-elderly_COR-2020-12-104 
author = {Minehiko Inomata,Kenji  Azechi,Naoki  Takata,Kana  Hayashi,Kotaro  Tokui,Chihiro  Taka,Seisuke  Okazawa,Kenta  Kambara,Shingo  Imanishi,Toshiro  Miwa,Ryuji  Hayashi,Shoko  Matsui,Kazuyuki  Tobe,}
keywords = { Elderly, immune checkpoint inhibitor, lung cancer}
abstract ={Purpose: We analysed the relationship between a history of immune checkpoint inhibitor (ICI) and overall
survival in elderly patients with non-small cell lung cancer (NSCLC).
Methods: We conducted a retrospective analysis of the data of patients with NSCLC aged ≥70-year-old
who had received systemic anticancer therapy between 2015 and 2019.
Results: The analysis included the data of a total of 63 patients. Multivariate analysis revealed a significant
association between a history of treatment with ICI and the overall survival. A significant interaction was
also observed between a history of treatment with an ICI and the tumor histology.
Conclusion: A significant association between history of ICI therapy and the overall survival was detected
in elderly NSCLC patients aged ≥70-year-old in a clinical practice setting. Our results also suggested that
the impact of ICI therapy on the survival differed depending on the tumor histology.
}